CRYSTAL DYER: Open Payments
NPI 1053861609 · JOPLIN, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,238 in 76 payments from 19 companies in 2025. Trend: 2023 $993 · 2024 $958 · 2025 $1,238
Food & beverage: $1,238
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $227 |
| ABBVIE INC. | 14 | $147 |
| Teva Pharmaceuticals USA, Inc. | 10 | $136 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $135 |
| Otsuka America Pharmaceutical, Inc. | 4 | $82 |
| Lilly USA, LLC | 3 | $57 |
| Phathom Pharmaceuticals, Inc. | 4 | $56 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $48 |
| Novo Nordisk Inc | 3 | $45 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
Products named: CAPLYTA, BREZTRI, VRAYLAR, REXULTI, UZEDY, FARXIGA, JARDIANCE, VOQUEZNA.
Industry payments across MO — which companies pay providers there.
